FEXTRIC 180

Main information

  • Trade name:
  • FEXTRIC 180 10
  • Composition:
  • 10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FEXTRIC 180 10
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

29-5-2017

Lupin Pharmaceuticals Inc. Announces a Nationwide Recall of Mibelas™ 24 Fe (Norethindrone Acetate and EthinylEstradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75 mg) Tablets Due to Out of Sequence Tablets and Missing Expiry/Lot Information

Lupin Pharmaceuticals Inc. Announces a Nationwide Recall of Mibelas™ 24 Fe (Norethindrone Acetate and EthinylEstradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75 mg) Tablets Due to Out of Sequence Tablets and Missing Expiry/Lot Information

Baltimore, Maryland, Lupin Pharmaceuticals Inc. announced today that it has voluntarily recalled lot L600518, Exp 05/18 of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1 mg/0.02 mg chewable and ferrous fumarate 75 mg) Tablets at the consumer level. A confirmed market complaint indicated a packaging error, where the blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiration date no longer visible. The first four days of...

FDA - U.S. Food and Drug Administration

10-7-2017

EU/3/14/1249 (Akcea Therapeutics UK Ltd.)

EU/3/14/1249 (Akcea Therapeutics UK Ltd.)

EU/3/14/1249 (Active substance: Phosphorothioate oligonucleotide targeted to apolipoprotein C-III) - Transfer of orphan designation - Commission Decision (2017)4921 of Mon, 10 Jul 2017 European Medicines Agency (EMA) procedure number: EMA/OD/180/13/T/01

Europe -DG Health and Food Safety